The breadth and depth of the TOURMALINE program allows us to gather important data across a broad range of patients that live with multiple myeloma and to expand on the efficacy and safety profile of our oral proteasome inhibitor
We are excited to offer patients the first oral proteasome inhibitor
as an alternative treatment option for those with multiple myeloma," said Gary Kadlec, president of Diplomat.
The multi-center study with MLN9708, an investigational, oral proteasome inhibitor
, will be conducted in Europe and North America.
In July 2012, the market reached a new milestone with the approval of Onyx's Kyprolis, a proteasome inhibitor
with an improved safety profile and potential to be another blockbuster.
Phase 1 trial of the proteasome inhibitor
PS-341 in patients with refractory hematologic malignancies.
Velcade, developed by Millennium Pharmaceuticals that was acquired by Takeda, was the first proteasome inhibitor
Building upon early stage microbial discoveries by researchers at the University of California, San Diego's Scripps Institution of Oceanography, Nereus is developing a novel and highly selective tumour vascular disrupting agent (VDA; NPI-2358) derived from a marine fungus and a potent second generation proteasome inhibitor
(NPI-0052) isolated from a novel marine bacteria.
VELCADE (bortezomib) for Injection, the market leader for multiple myeloma and mantle cell lymphoma patients, who have received at least one prior therapy, is the first and only marketed proteasome inhibitor
To demonstrate that this peptide bond hydrolysis was actually catalyzed by circulating proteasomes, we repeated the assay in the presence of the proteasome inhibitor
lactacystin and found that at a concentration of 1 [micro]mol/L lactacystin inhibited the activity almost quantitatively.
Last year, the Food and Drug Administration approved the proteasome inhibitor
bortezomib (Velcade) for the treatment of multiple myeloma, a cancer of the blood.
Cells treatments were: vehicle only (control); proteasome inhibitor
(MG132); calpain inhibitor (ALLN) and estrogen for 24 hrs.
The FDA decision follows the recent approval of KYPROLIS([R]), a second-generation proteasome inhibitor
for myeloma patients who have relapsed after previous therapies.